Insulin-Like Growth Factor Binding Protein 1

One of the six homologous proteins that specifically bind insulin-like growth factors (SOMATOMEDINS) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits IGF binding to cell surface receptors and thereby inhibits IGF-mediated mitogenic and cell metabolic actions. (Proc Soc Exp Biol Med 1993;204(1):4-29)

Also Known As:

Networked: 672 relevant articles (14 outcomes, 95 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Brismar, Kerstin: 19 articles (12/2015 - 04/2004)
2.	Pollak, Michael N: 14 articles (05/2015 - 05/2003)
3.	Kaaks, Rudolf: 14 articles (03/2011 - 05/2002)
4.	Brismar, K: 12 articles (06/2013 - 03/2000)
5.	Rinaldi, Sabina: 11 articles (03/2011 - 05/2002)
6.	Riboli, Elio: 10 articles (03/2011 - 05/2002)
7.	Frystyk, Jan: 9 articles (11/2015 - 10/2003)
8.	Flyvbjerg, Allan: 8 articles (11/2015 - 01/2004)
9.	Peeters, Petra H M: 7 articles (03/2011 - 08/2003)
10.	Lacinová, Z: 7 articles (01/2006 - 08/2001)

Related Diseases

1.	Body Weight (Weight, Body) 11/01/1995 - "IGFBP-1 administration was, however, associated with a significantly greater loss of body weight (P < 0.05), indicating that the peptide had a profound metabolic effect. " 01/01/2006 - "Plasma IGFBP-1 was measured in individually tagged 1-year-old coho salmon reared for 10 weeks under four different feeding regimes as follows: high constant (2% body weight/day), medium constant (1% body weight/day), high variable (2% to 0.5% body weight/day) and medium variable (1% to 0.5% body weight/day). " 07/01/1997 - "In addition, body weight in adult mice was negatively correlated to plasma concentrations of IGFBP-1 (r = 0.7, P < 0.0001). " 01/01/1993 - "Serum IGF binding activity and levels of IGFBP-1 also are high in the hypoinsulinemic SGA fetal rat and levels of IGFBP-1 correlate with fetal liver and body weight, indicating that IGFBP-1 contributes to the regulation of somatic growth in utero. " 09/01/2010 - "We found that serum IGF-I during pregnancy was positively correlated with maternal body weight (r 0.47-0.56) and fat-free body weight (r 0.61-0.65), whereas serum IGFBP-1 was negatively correlated with maternal body weight (r - 0.44 to - 0.69) and body fat (r - 0.64 to - 0.76) before and during pregnancy. "
2.	Critical Illness (Critically Ill) 12/01/2001 - "Initial evidence suggests that the level of IGFBP-1 may be predictive of outcome in critically ill patients, suggesting a possible prognostic role for this protein." 04/01/2008 - "High levels of IGFBP-1 are encountered in critically ill patients and are a good predictor marker in acute myocardial infarction. " 06/01/2003 - "A lethal outcome of critical illness is predicted by a high serum concentration of IGFBP-1, pointing to impaired insulin effect rather than pituitary function, and survival was recently shown to be dramatically improved by strict normalization of glycemia with exogenous insulin. " 10/01/2002 - "A lethal outcome of critical illness is predicted by a high serum concentration of IGF-binding protein 1, pointing to impaired insulin effect rather than pituitary function, and survival was recently shown to be dramatically improved by strict normalization of glycemia with exogenous insulin. " 01/01/2002 - "Protein turnover but not lipolysis correlated with a persisting critically ill condition, serum prealbumin, RBP, and plasma IGFBP-1."
3.	Neoplasms (Cancer) 04/01/2015 - "The intention of this work was to systematically study the presence of insulin-like growth factor-binding protein 1 and 2 (IGFBP-1 and IGFBP-2) complexes with alpha-2-macroglobulin (α2M) in the circulation of patients with various types of cancer. " 05/01/2015 - "In contrast, IGFBP-1 protein expression was low in MMTV-Neu tumors regardless of Mmp9 status. " 06/01/2012 - "The adjusted hazard ratio per sd of IGFBP-1 change was 1.40 for overall cancer mortality (95% confidence interval = 1.10, 1.77; P = 0.01) and 1.14 for noncancer mortality (95% confidence interval = 1.02, 1.27; P = 0.02). " 08/01/2002 - "Moreover, IGFBP-1 could have dual effects on cancer cell motility by disrupting both receptor systems." 04/01/2001 - "The results suggest cell type-specific accumulation of IGFBP-1, -2, and -3 in human glial tumors of the brain. "
4.	Rupture 01/01/2015 - "The aim of this study was to evaluate the clinical application of a novel method immunomagnetic reduction (IMR) for quantitative measurement of IGFBP-1 concentrations in the cervicovaginal secretions to diagnose pregnant women with preterm premature rupture of membranes (PPROM). " 05/01/2013 - "The aim of this study was to compare the performance of tests based on the detection of insulin-like growth factor binding protein 1 (IGFBP-1) and placental α-microglobulin-1 (PAMG-1) in diagnosing rupture of fetal membranes (ROM) across different patient populations. " 12/01/2013 - "Premature preterm rupture of the membrane diagnosis in early pregnancy: PAMG-1 and IGFBP-1 detection in amniotic fluid with biochemical tests." 11/01/1999 - "[Insulin-like growth factor binding protein 1 (IGFBP-1) in vaginal secretion as a marker of premature rupture of amniotic membranes]." 12/01/1998 - "A PROM test [dipstick detecting IGFBP-1 with a cutoff value of 25 micrograms/l (A)], a BTB test (B), a ROM-Check (C), and a fern test (D) were compared in diagnosing ruptures of the membranes in 48 patients. "
5.	Prostatic Neoplasms (Prostate Cancer) 12/01/2011 - "Circulating insulin-like growth factor binding protein 1 (IGFBP1) levels vary in response to nutritional status, and pre-clinical studies suggest that elevated IGFBP1 may be protective against the development and progression of prostate cancer. " 05/15/2015 - "In summary, prediagnostic fasting IGFBP-1 may influence prostate cancer carcinogenesis. " 02/01/2014 - "Elevated IGFBP-1 appears to be associated with shorter time to CRPC and lower overall survival in men with metastatic prostate cancer." 06/01/2001 - "Similarly, IGFBP-1 was inversely associated with prostate cancer risk only among men with the ff FokI genotype (odds ratio, 0.25; 95% confidence interval, 0.07-0.85; P(trend) = 0.02). " 09/01/2000 - "Expression of the IGF system, except IGFBP-1, was detected in all prostate cancer tissue samples. "

Related Drugs and Biologics

1.	Insulin-Like Growth Factor I (IGF-1)
2.	Insulin (Novolin)
3.	Glucose (Dextrose)
4.	Insulin-Like Growth Factor Binding Protein 3
5.	Insulin-Like Growth Factor Binding Proteins
6.	C-Peptide
7.	Proteins (Proteins, Gene)
8.	Progesterone
9.	alpha-Fetoproteins (AFP)
10.	Hydrocortisone (Cortisol)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Renal Dialysis (Hemodialysis)
3.	Artificial Pancreas
4.	Heterologous Transplantation (Xenotransplantation)
5.	Caloric Restriction